Brief: Calliditas Therapeutics: Full Results From Nefigard Phase 3 Trial Published In Lancet
15/08/2023 07:21
Aug 15 (Reuters) - Calliditas Therapeutics AB
CALTX.ST :
* CALLIDITAS THERAPEUTICS ANNOUNCES FULL RESULTS FROM THE
NEFIGARD
PHASE 3 TRIAL PUBLISHED IN THE LANCET
* PHASE 3 TRIAL MET PRIMARY ENDPOINT, ESTIMATED GLOMERULAR
FILTRATION RATE (EGFR), WITH NEFECON DEMONSTRATING SIGNIFICANT
KIDNEY PROTECTIVE EFFECT OVER PLACEBO.
Source text for Eikon: ID:nWkr6wRkgY
Further company coverage: CALTX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations